HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

EGFR-Mutant NSCLC: Is There A Role For Combined Therapy?

Of course being diagnosed with metastatic non-small cell lung cancer (NSCLC) feels overwhelming. Between juggling treatments, managing symptoms and side effects, and dealing with the anxiety of a ...

Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with ...

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest ...

NSCLC is the most common type of lung cancer. About 80 to 85% of all lung carcinomas are NSCLC. Stage 4 indicates the cancer has spread to distant tissues. NSCLC stage 4 has a 5-year relative survival ...

Sabari, MD, discusses exploring combination approaches as the next research step with zongertinib in patients with HER2 ...

EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

EGFR mutations significantly influence NSCLC treatment, with osimertinib showing superior PFS over first-generation TKIs, but resistance remains a challenge. Combination therapies, such as osimertinib ...